Epizyme Announces Closing of Public Offering of Common Stock & Full Exercise of Underwriter’s Option to Purchase Additional...
October 05 2018 - 4:05PM
Business Wire
Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company
developing novel epigenetic therapies, today announced the closing
of its underwritten public offering of 9,583,334 shares of its
common stock at a public offering price of $9.00 per share, which
includes 1,250,000 shares issued upon the exercise in full by the
underwriter of its option to purchase additional shares at the
public offering price less the underwriting discount.
The aggregate gross proceeds to Epizyme from the offering,
before deducting underwriting discounts and offering expenses, are
$86.25 million.
Epizyme anticipates using the net proceeds from this offering,
together with its existing cash, cash equivalents and marketable
securities to fund global development and commercialization costs
of tazemetostat outside of Japan, including the costs of Epizyme’s
ongoing and planned clinical trials of tazemetostat, the costs of
regulatory activities related to tazemetostat, including associated
milestone payments, and the costs associated with the commercial
launch of tazemetostat for epithelioid sarcoma, if approved; to
fund research and development costs to develop other product
candidates, including EZM8266 for sickle cell disease; and for
working capital and other general corporate purposes.
Jefferies acted as sole book-running manager for the
offering.
A shelf registration statement relating to the shares of common
stock offered in the public offering was filed with the Securities
and Exchange Commission ("SEC") on April 5, 2018 and was
automatically effective upon filing. The offering was made only by
means of a written prospectus and prospectus supplement that form a
part of the registration statement. A prospectus supplement
relating to and describing the terms of the offering has been filed
with the SEC and is available on the SEC's website at www.sec.gov.
Copies of the prospectus supplement and the accompanying prospectus
relating to the securities being offered may also be obtained by
contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or
by telephone at (877) 821-7388, or by email at
Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
the securities being offered in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or other jurisdiction.
About Epizyme, Inc.Epizyme,
Inc. is a clinical-stage biopharmaceutical company committed to
rewriting treatment for cancer and other serious diseases through
novel epigenetic medicines. Epizyme is broadly developing its lead
product candidate, tazemetostat, a first-in-class EZH2 inhibitor,
with studies underway in both solid tumors and hematological
malignancies, as a monotherapy and combination therapy in relapsed
and front-line disease. The company is also developing a novel G9a
program with its next development candidate, EZM8266, which is
targeting sickle cell disease. By focusing on the genetic drivers
of disease, Epizyme's science seeks to match targeted medicines
with the patients who need them.
Cautionary Note on Forward-Looking
StatementsAny statements in this press release about
future expectations, plans and prospects for Epizyme, Inc.,
including statements about the company's public offering,
anticipated use of proceeds, future operations, clinical
development of the company's therapeutic candidates, expectations
regarding future clinical trials and future expectations and plans
and prospects for the company and other statements containing the
words "anticipate," "believe," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including:
uncertainties inherent in the initiation of future clinical trials
and other factors discussed in the "Risk Factors" section of the
prospectus supplement filed with the SEC on October 3, 2018, the
company's most recent Form 10-Q filed with the SEC and in the
company’s other filings from time to time with the SEC. In
addition, the forward-looking statements included in this press
release represent the company's views as of the date hereof and
should not be relied upon as representing the company's views as of
any date subsequent to the date hereof. The company anticipates
that subsequent events and developments will cause the company's
views to change. However, while the company may elect to update
these forward-looking statements at some point in the future, the
company specifically disclaims any obligation to do so.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181005005373/en/
Media:Epizyme, Inc.Erin Graves,
617-500-0615media@epizyme.comorInvestors:THRUST Strategic
CommunicationsMonique Allaire, 617-895-9511monique@thrustsc.com
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Apr 2023 to Apr 2024